Web Stats Provided By Google Analytics

Sunday, February 2, 2014

3 Reasons for GlaxoSmithKline to Cheer

The study compared those results with the single agent therapy of Tafinlar, and furthermore, the company expects to receive additional positive results when the combination of the two drugs is compared to Vemurafenib later in the year.

http://ift.tt/LEDqKD

No comments:

Post a Comment